Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 951-955

  Kruit, W H J ^a   Punt, C J A ^b   Goey, S H ^a   De Mulder, P H M ^b   Gratama, J W ^a   Eggermont, A M M ^a   Bolhuis, R L H ^a   Stoter, G ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Interferon alpha; Interleukin 2; Metastatic melanoma

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DYSPNEA; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROPSYCHIATRY; NEUROTOXICITY; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 0029775131     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.463     Document Type: Article

References (25)

1. ATKINS MB, SPARANO J, FISHER RI, WEISS GR, MARGOLIN KA, FINK KI, RUBINSTEIN L, LOUIE A, MIER JW, GUCALP R, SOSMAN JA, BOLDT DH, DOROSHOW JH, ARONSON FR AND SZNOL M. (1993). Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J. Clin. Oncol., 11, 661-670.
2. BAR MH, SZNOL M, ATKINS MB, CIOBANU N, MICETICH KC, BOLDT DH, MARGOLIN KA, ARONSON FR, RAYNER AA, HAWKINS MJ, MIER JW, PAIETTA E, FISHER RI, WEISS GR AND DOROSHOW JH. (1990). Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J. Clin. Oncol., 8, 1138-1147.
3. CREAGAN ET, SCHAID DJ, AHMANN DL AND FRYTAK S. (1990). Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J. Invest. Dermatol., 95, 118S-192S.
4. DENICOFF KD, RUBINOW DR, PAPA MZ, SIMPSON C, SEIPP CA, LOTZE MT, CHANG AE, ROSENSTEIN D AND ROSENBERG SA. (1987). The neuro-psychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann. Intern. Med., 107, 293-300.
5. DILLMAN RO, CHURCH C, OLDHAM RK, WEST WH, SCHWARTZBERG L AND BIRCH R. (1993). Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The national biotherapy study group experience. Cancer, 71, 2358-2370.
6. DUTCHER JP, GAYNOR ER, BOLDT DH, DOROSHOW JH, BAR MH, SZNOL M, MIER J, SPARANO J, FISHER RI, WEISS G, MARGOLIN K, ARONSON FR, HAWKINS M AND ATKINS M. (1991). A phase II study of high-dose continuous infusion interleukin-2 lymphokine-activated killer cells in patients with metastatic melanoma. J. Clin. Oncol., 9, 641-648.
7. FOSSÅ SD, AUNE H, BAGGERUD E, GRANERUD T, HEILO A AND THEODORSEN L. (1993). Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic renal cell carcinoma. Eur. J. Cancer, 29A, 1313-1315.
8. GRATAMA JW, SCHMITZ PIM, GOEY SH, LAMERS CHJ, STOTER G AND BOLHUIS RLH. (1996). Modulation of immune parameters in patients with metastatic renal cell cancer receiving combination immunotherapy (IL-2, IFNα and autologous IL-2 activated lymphocytes). Int. J. Cancer, 65, 152-160.
9. KEILHOLZ U, SCHEIBENBOGEN C, TILGEN W, BERGMANN L, WEIDMANN E, SEITHER E, RICHTER M, BRADO B, MITROU PS AND HUNSTEIN W. (1993). Interferon-α and interleukin-2 in the treatment of metastatic malanoma. Comparison of two phase II trials. Cancer, 72, 607-614.
10. KHAYAT D, BOREL C, TOURANI JM, BENHAMMOUDA A, ANTOINE E, RIXE O, VUILLEMIN E, BAZEX PA, THILL L, FRANKS R, AUCLERC G, SOUBRANE C, BANZET P AND WEIL M. (1993). Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol., 11, 2173-2180.
11. KIRKWOOD JM. (1991). Studies of interferons in the therapy of melanoma. Semin. Oncol., 18, (suppl. 7) 83-89.
12. KRUIT WHJ, PUNT CJA, GOEY SH, DE MULDER PH, VAN HOOGENHUIJZE DC, HENZEN-LOGMANS SC AND STOTER G. (1994). Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. Cancer, 74, 1850-1856.
13. KRUIT WHJ, GOEY SH, CALABRESI F, LINDEMANN A, STAHEL RA, POLIWODA H, OSTERWALDER B AND STOTER G. (1995). Final report of a phase II study of interleukin-2 and interferon-α in patients with metastatic melanoma. Br. J. Cancer, 71, 1319-1321.
14. LEGHA SS AND BUZAID AC. (1993). Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Sem. Oncol., 20, (suppl), 27-32.
15. MARINCOLA FM, WHITE DE, WISE AP AND ROSENBERG SA. (1995). Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol., 13, 1110-1122.
16. PARKINSON DR, ABRAMS JS, WIERNIK PH, RAYNER AA, MARGOLIN KA, VAN ECHO DA, SZNOL M, DUTCHER JP, ARONSON FR, DOROSHOW JH, ATKINS MB AND HAWKINS MJ. (1990). Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol., 8, 1650-1656.
17. RICHARDS JM, MEHTA N, RAMMING K AND SKOSEY P. (1992). Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol., 10, 1338-1343.
18. ROSENBERG SA, LOTZE MT, YANG JC, AEBERSOLD PM, LINEHAN WM, SEIPP CA AND WHITE DE. (1989a). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210, 474-485.
19. ROSENBERG SA, LOTZE MT, YANG JC, LINEHAN WM, SEIPP CA, CALABRO S, KARP SE, SHERRY RM, STEINBERG S AND WHITE DE. (1989b). Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7, 1863-1874.
20. ROSENBERG SA, LOTZE MT, YANG JC, TOPALIAN S, CHANG AE, SCHWARTZENTRUBER DJ, AEBERSOLD P, LEITMAN S, LINEHAN WM, SEIPP CA, WHITE DE AND STEINBERG SM. (1992). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst., 85, 622-632.
21. ROSENBERG SA, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, WEBER JS, PARKINSON DR, SEIPP CA, EINHORN JH AND WHITE DE. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA, 271, 907-913.
22. SPARANO JA, FISHER RI, SUNDERLAND M, MARGOLIN K, ERNEST ML, SZNOL M, ATKINS MB, DUTCHER JP, MICETICH KC, WEISS GR, DOROSHOW JH, ARONSON FR, RUBINSTEIN LV AND MIER JW. (1993). Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J. Clin. Oncol., 11, 1969-1977.
23. SZNOL M, CLARK JW, SMITH JW, STEIS RG, URBA WJ, RUBINSTEIN LV, VANDERMOLEN LA, JANIK J, SHARFMAN WH, FENTON RG, CREEKMOORE SP, KREMERS P, CONLON K, HURSEY J, BEVERIDGE J AND LONGO DL. (1992). Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl Cancer Inst., 84, 929-937.
24. WHITEHEAD RP, KOPECKY KJ, SAMSON MK, COSTANZI JJ, NATALE RB, FEUN LG, HERSH EM AND RINEHART JJ (1991). Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma. J. Natl Cancer Inst., 83, 1250-1252.
25. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva.